Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Point

View More View Less
  • a From The Division of Infectious Diseases, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, and Johannes Gutenberg-University, Mainz, Germany.

Invasive fungal infections (IFIs) are a leading cause of infection-related mortality in patients with acute leukemia and prolonged neutropenia and in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD). Although invasive candidiasis was the principal IFI predating fluconazole prophylaxis, invasive aspergillosis and other mold infections now cause most deaths from fungal infection in this patient population. The availability of broad-spectrum antifungal agents that can be safely administered over prolonged periods has stimulated interest in using mold-active prophylactic agents early as prophylaxis rather than later as therapy for suspected or documented IFIs. Two recent, prospective, randomized trials have shown a clear benefit of posaconazole prophylaxis in patients with myelodysplastic syndrome and acute mye-logenous leukemia with prolonged neutropenia and in allogeneic HSCT recipients with severe GVHD. In contrast, the peer-reviewed published database on the strategy of preemptive antifungal therapy, in which yeast-active prophylaxis (fluconazole) or no antifungal prophylaxis is used initially and modifications are triggered by a combination of laboratory markers and chest CT scans, is currently limited to an open-label feasibility study. Does sufficient evidence currently exist that the net benefit of the preemptive approach is at least on a par with posaconazole prophylaxis in the specific patient groups that were studied? The authors believe not and that more research is needed before the pre-emptive strategy can be recommended.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Brahm H. Segal, MD, Division of Infectious Diseases, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263. E-mail: brahm.segal@roswellpark.org
  • 1.

    Ascioglu S, Rex JH, de Pauw B. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:714.

    • Search Google Scholar
    • Export Citation
  • 2.

    Segal BH, Almyroudis NG, Battiwalla M. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402409.

    • Search Google Scholar
    • Export Citation
  • 3.

    Segal BH, Freifeld AG. Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw 2007;5:235242.

  • 4.

    Kuhlman JE, Fishman EK, Burch PA. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987;92:9599.

    • Search Google Scholar
    • Export Citation
  • 5.

    Caillot D, Casasnovas O, Bernard A. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139147.

    • Search Google Scholar
    • Export Citation
  • 6.

    Caillot D, Couaillier JF, Bernard A. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253259.

    • Search Google Scholar
    • Export Citation
  • 7.

    Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173:707717.

  • 8.

    Freifeld AG, Segal BH, Baden LR. NCCN Prevention and treatment of cancer-related infections guidelines update. Presented at the 12th Annual NCCN conference; Hollywood, Florida; March 17, 2007.

    • Search Google Scholar
    • Export Citation
  • 9.

    Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003;5:158166.

  • 10.

    Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349357.

    • Search Google Scholar
    • Export Citation
  • 11.

    Marr KA, Balajee SA, McLaughlin L. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641649.

    • Search Google Scholar
    • Export Citation
  • 12.

    Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:17621769.

    • Search Google Scholar
    • Export Citation
  • 13.

    Herbrecht R, Letscher-Bru V, Oprea C. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:18981906.

    • Search Google Scholar
    • Export Citation
  • 14.

    Walsh TJ, Shoham S, Petraitiene R. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004;42:47444748.

    • Search Google Scholar
    • Export Citation
  • 15.

    Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:23662367.

    • Search Google Scholar
    • Export Citation
  • 16.

    Maertens J, Van Eldere J, Verhaegen J. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:12971306.

    • Search Google Scholar
    • Export Citation
  • 17.

    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:14171727.

    • Search Google Scholar
    • Export Citation
  • 18.

    Odabasi Z, Mattiuzzi G, Estey E. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199205.

    • Search Google Scholar
    • Export Citation
  • 19.

    Ostrosky-Zeichner L, Alexander BD, Kett DH. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654659.

    • Search Google Scholar
    • Export Citation
  • 20.

    Marty FM, Lowry CM, Lempitski SJ. Reactivity of (1→3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006;50:34503453.

    • Search Google Scholar
    • Export Citation
  • 21.

    Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006;354:28342835.

    • Search Google Scholar
    • Export Citation
  • 22.

    Ogawa M, Hori H, Niiguchi S. False-positive plasma (1→3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004;80:9798.

    • Search Google Scholar
    • Export Citation
  • 23.

    Rotstein C, Bow EJ, Laverdiere M. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331340.

    • Search Google Scholar
    • Export Citation
  • 24.

    Kern W, Behre G, Rudolf T. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291301.

    • Search Google Scholar
    • Export Citation
  • 25.

    Winston DJ, Chandrasekar PH, Lazarus HM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. Ann Intern Med 1993;118:495503.

    • Search Google Scholar
    • Export Citation
  • 26.

    Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 27.

    Goodman JL, Winston DJ, Greenfield RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation [see comments]. N Engl J Med 1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 28.

    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 29.

    Bodey GP, Mardani M, Hanna HA. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380385.

    • Search Google Scholar
    • Export Citation
  • 30.

    Kanda Y, Yamamoto R, Chizuka A. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:16111625.

    • Search Google Scholar
    • Export Citation
  • 31.

    van Burik JH, Leisenring W, Myerson D. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998;77:246254.

    • Search Google Scholar
    • Export Citation
  • 32.

    Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation [see comments]. J Infect Dis 1997;175:14591466.

    • Search Google Scholar
    • Export Citation
  • 33.

    Marr KA, Carter RA, Crippa F. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909917.

    • Search Google Scholar
    • Export Citation
  • 34.

    Chamilos G, Luna M, Lewis RE. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006;91:986989.

    • Search Google Scholar
    • Export Citation
  • 35.

    Nucci M, Marr KA, Queiroz-Telles F. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004;38:12371242.

  • 36.

    Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997;90:9991008.

    • Search Google Scholar
    • Export Citation
  • 37.

    Kontoyiannis DP, Bodey GP, Hanna H. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004;45:139141.

    • Search Google Scholar
    • Export Citation
  • 38.

    Walsh TJ, Groll A, Hiemenz J. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004;10(Suppl 1):4866.

    • Search Google Scholar
    • Export Citation
  • 39.

    Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002;17:113120.

    • Search Google Scholar
    • Export Citation
  • 40.

    Imhof A, Balajee SA, Fredricks DN. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743746.

    • Search Google Scholar
    • Export Citation
  • 41.

    Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950952.

    • Search Google Scholar
    • Export Citation
  • 42.

    Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J Infect Dis 2005;191:13501360.

    • Search Google Scholar
    • Export Citation
  • 43.

    Marr KA, Crippa F, Leisenring W. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2003;2:2.

    • Search Google Scholar
    • Export Citation
  • 44.

    Winston DJ, Maziarz RT, Chandrasekar PH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705713.

    • Search Google Scholar
    • Export Citation
  • 45.

    Marr KA, Leisenring W, Crippa F. Cyclophosphamide metabolism is impacted by azole antifungals. Blood 2003;22:22.

  • 46.

    van Burik JA, Ratanatharathorn V, Stepan DE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:14071416.

    • Search Google Scholar
    • Export Citation
  • 47.

    Kontoyiannis DP, Hare R, Solomon H. Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC M-974 2005.

    • Search Google Scholar
    • Export Citation
  • 48.

    Greenberg RN, Mullane K, van Burik JA. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126133.

  • 49.

    Raad II, Graybill JR, Bustamante AB. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:17261734.

    • Search Google Scholar
    • Export Citation
  • 50.

    Raad II, Hachem RY, Herbrecht R. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:13981403.

    • Search Google Scholar
    • Export Citation
  • 51.

    Walsh TJ, Raad I, Patterson TF. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:212.

    • Search Google Scholar
    • Export Citation
  • 52.

    Vazquez JA, Skiest DJ, Nieto L. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:11791186.

    • Search Google Scholar
    • Export Citation
  • 53.

    Cornely OA, Maertens J, Winston DJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 54.

    Ullmann AJ, Lipton JH, Vesole DH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 55.

    Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804808.

    • Search Google Scholar
    • Export Citation
  • 56.

    De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 2007;356:409411.

  • 57.

    Maertens J, Theunissen K, Verhoef G. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:12421250.

    • Search Google Scholar
    • Export Citation
  • 58.

    Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 2004;39(Suppl 4):S176180.

    • Search Google Scholar
    • Export Citation
  • 59.

    Wingard JR, Carter SL, Walsh TJ. The Blood and Marrow Transplant Clinical Trials Network. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients [abstract]. Blood 2007;110: Abstract 163.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 153 71 1
PDF Downloads 38 26 1
EPUB Downloads 0 0 0